The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
The role of stromal cells and the tumour microenvironment in general in modulating tumour sensitivity is increasingly becoming a key consideration for the development of active anticancer therapeutics. Here, we discuss how these tumour-stromal interactions affect tumour cell signalling, survival, proliferation and drug sensitivity. Particular emphasis is placed on the ability of stromal cells to confer - to tumour cells - resistance or sensitization to different classes of therapeutics, depending on the specific microenvironmental context. The mechanistic understanding of these microenvironmental interactions can influence the evaluation and selection of candidate agents for various cancers, in both the primary site as well as the metastatic setting. Progress in in vitro screening platforms as well as orthotopic and 'orthometastatic' xenograft mouse models has enabled comprehensive characterization of the impact of the tumour microenvironment on therapeutic efficacy. These recent advances can hopefully bridge the gap between preclinical studies and clinical trials of anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“Hence, tumor-stromal interactions, the composition of the TME and tumor immune status all contribute to determining tumor growth, metastasis, angiogenesis and therapy resistance (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021), thereby critically influencing the clinical outcome of cancer patients.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“In addition, many studies have highlighted the critical importance of the microenvironment for promoting or suppressing tumor growth, invasion, metastasis, and response to therapy (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“The non‐malignant cells and matrixcomponents which make up the TME have been shown to playa role in tumor cell survival, proliferation,andtreatment resistance (48).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [48]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Three-dimensional in vitro cell culture models in drug discovery and drug repositioning
Langhans, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00006 · Cited by 1,522
“…altered local drug availability, by affecting expression of drug targets, or by changing intrinsic cellular defense mechanisms such as increased repair upon DNA damage or evasion of apoptosis (Sebens and Schafer, 2012; Junttila and de Sauvage, 2013; McMillin et al., 2013; Holle et al., 2016).”
BackgroundAngiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review
Azmi, A. S., Bao, B., & Sarkar, F. H. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9441-9 · Cited by 1,167
“The development of resistance is multifactorial that includes switching of cancer cells to secondary salvage pathways when the primary hallmark is shut [133], epigenetic suppression of tumor suppressor protein activation by miRNAs [134], presence of a subpopulation of highly resistant cancer stem-like cells with enhan…”
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926
“The mechanism for this unexpected sensitization may include the alteration of signaling pathways in neoplastic cells that are induced by CAFs (McMillin et al., 2013).”
Background3D tumor spheroids: an overview on the tools and techniques used for their analysis
Costa, E. C., Moreira, A. F., de Melo-Diogo, D., Gaspar, V. M., Carvalho, M. P., & Correia, I. J. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.11.002 · Cited by 929
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
Boelens, M. C., Wu, T. J., Nabet, B. Y., Xu, B., Qiu, Y., Yoon, T., Azzam, D. J., Twyman-Saint Victor, C., Wiemann, B. Z., Ishwaran, H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.051 · Cited by 806
“Stromal cells, which are primarily fibroblasts but can also be other cell types, can promote survival after genotoxic and targeted therapy through the secretion of paracrine factors (McMillin et al., 2013).”
BackgroundMicroenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 771
Labernadie, A., Kato, T., Brugués, A., Serra-Picamal, X., Derzsi, S., Arwert, E., Weston, A., González-Tarragó, V., Elosegui-Artola, A., Albertazzi, L., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3478 · Cited by 747
“Three classes of duration time were defined: longer than 60 min (>60), between 30 to 60 min (30-60) and less than 30 min (<30).”
BackgroundAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
“These studies reflect a growing paradigm that the tumour stroma plays an important role in therapy resistance [150, 154, 156, 157].”
BackgroundNew horizons in tumor microenvironment biology: challenges and opportunities
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y. (2015) · BMC Medicine · doi:10.1186/s12916-015-0278-7 · Cited by 704
“Recent studies intensively evaluated the functional roles of TME in protecting acute myeloid leukemia cells or chronic lymphocytic leukemia cells against alkylating agents, anthracyclines, imatinib and nucleoside analogues, mutant Janus kinase 2 (JAK2) cells against JAK inhibitors including tofacitinib and ruxolitinib…”
BackgroundThe tumour microenvironment in B cell lymphomas
Scott, D. W., & Gascoyne, R. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3774 · Cited by 552
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
Hoarau-Véchot, J., Rafii, A., Touboul, C., & Pasquier, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010181 · Cited by 489
“This complexity is partly due to the interaction between the tumor and its microenvironment [1,2].”
BackgroundTumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Shi, Y., Du, L., Lin, L., & Wang, Y. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.193 · Cited by 460
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C.-L., Skhinas, J. N., Collot, R., Yang, J., Harvey, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05220-6 · Cited by 437
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Binenbaum, Y., Na’ara, S., & Gil, Z. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.002 · Cited by 414
Ma, X., Liu, J., Zhu, W., Tang, M., Lawrence, N., Yu, C., Gou, M., & Chen, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.011 · Cited by 401
Exosomes in the tumor microenvironment as mediators of cancer therapy resistance
Li, I., & Nabet, B. Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0975-5 · Cited by 416
3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions
Rodrigues, J., Heinrich, M. A., Teixeira, L. M., & Prakash, J. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2020.10.009 · Cited by 405
Tumor microenvironment and cancer therapy resistance
Sun, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.07.044 · Cited by 381
Ruggeri, B. A., Camp, F., & Miknyoczki, S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.020 · Cited by 365
Binenbaum, Y., Fridman, E., Yaari, Z., Milman, N., Schroeder, A., Ben David, G., Shlomi, T., & Gil, Z. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0124 · Cited by 337
Tailoring nanoparticle designs to target cancer based on tumor pathophysiology
Sykes, E. A., Dai, Q., Sarsons, C. D., Chen, J., Rocheleau, J. V., Hwang, D. M., Zheng, G., Cramb, D. T., Rinker, K. D., & Chan, W. C. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521265113 · Cited by 281
“As we learn more about the cellular, vascular, and 73 compositional characteristics of tumours, it is increasingly evident that tailoring drug delivery 74 vehicles to the physiological state of a tumour may be instrumental to improving treatment of 75 this disease (18, 19).”
BackgroundPersonalized Cancer Medicine: An Organoid Approach
Aboulkheyr Es, H., Montazeri, L., Aref, A. R., Vosough, M., & Baharvand, H. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.12.005 · Cited by 275
“Similar to the original tumor, PDX models can fully recapitulate the interactions of tumor cells with their surrounding stromal cells and the ECM, with the exception of interactions with the immune system.”
BackgroundInfluentialMetabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 246
Modeling neoplastic disease with spheroids and organoids
Zanoni, M., Cortesi, M., Zamagni, A., Arienti, C., Pignatta, S., & Tesei, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00931-0 · Cited by 261
“Of note, the direct interaction between stromal and cancer cells coupled with the release of cytokines, extracellular vesicles, and growth factors reconstitute the intricate signaling network of in vivo tumors [108].”
BackgroundFrismantas, V., Dobay, M. P., Rinaldi, A., Tchinda, J., Dunn, S. H., Kunz, J., Richter-Pechanska, P., Marovca, B., Pail, O., Jenni, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738070 · Cited by 262
“This protective effectmay even increase the stringency of drug testing.(32) We tested 60 preclinical and clinical compounds (supplemental Table 1) by using an imaging-based cell viability readout(21) (Figure 1) on ALL xenografts derived from patients with standard-risk or high-risk ALL based on MRD persistence and rel…”
MethodLiu, T., Zhang, X., Du, L., Wang, Y., Liu, X., Tian, H., Wang, L., Li, P., Zhao, Y., Duan, W., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0981-7 · Cited by 264
RetractedZhuang, J., Lu, Q., Shen, B., Huang, X., Shen, L., Zheng, X., Huang, R., Yan, J., & Guo, H. (2015) · Scientific Reports · doi:10.1038/srep11924 · Cited by 252
Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms
Hughes, D., & Andersson, D. I. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3922 · Cited by 245
Humanized Mouse Xenograft Models: Narrowing the Tumor–Microenvironment Gap
Morton, J. J., Bird, G., Refaeli, Y., & Jimeno, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1260 · Cited by 237
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
Ireland, L., Santos, A., Ahmed, M. S., Rainer, C., Nielsen, S. R., Quaranta, V., Weyer-Czernilofsky, U., Engle, D. D., Perez-Mancera, P. A., Coupland, S. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1201 · Cited by 243
“Drug resistance is one of the biggest challenges in cancer therapeutics and the cause of relapse in the majority of patients with cancer (1, 2).”
Roy, K., Wu, Y., Meitzler, J. L., Juhasz, A., Liu, H., Jiang, G., Lu, J., Antony, S., & Doroshow, J. H. (2015) · Clinical Science · doi:10.1042/cs20140542 · Cited by 229
The evolving relationship of wound healing and tumor stroma
Foster, D. S., Jones, R. E., Ransom, R. C., Longaker, M. T., & Norton, J. A. (2018) · JCI Insight · doi:10.1172/jci.insight.99911 · Cited by 223
Molecular and cellular paradigms of multidrug resistance in cancer
Vaidya, F. U., Sufiyan Chhipa, A., Mishra, V., Gupta, V. K., Rawat, S. G., Kumar, A., & Pathak, C. (2022) · Cancer Reports · doi:10.1002/cnr2.1291 · Cited by 197
3D tumor models: History, advances and future perspectives
Benien, P., & Swami, A. (2014) · Future Oncology · doi:10.2217/fon.13.274 · Cited by 208
CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer
Lin, L., Chen, Y.-S., Yao, Y.-D., Chen, J.-Q., Chen, J.-N., Huang, S.-Y., Zeng, Y.-J., Yao, H.-R., Zeng, S.-H., Fu, Y.-S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5325 · Cited by 198
Targeting CAFs to overcome anticancer therapeutic resistance
Saw, P. E., Chen, J., & Song, E. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.03.001 · Cited by 197
Organoid models of gastrointestinal cancers in basic and translational research
Lau, H. C. H., Kranenburg, O., Xiao, H., & Yu, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0255-2 · Cited by 194
Cytokines in cancer drug resistance: Cues to new therapeutic strategies
Jones, V. S., Huang, R.-Y., Chen, L.-P., Chen, Z.-S., Fu, L., & Huang, R.-P. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.005 · Cited by 195
Sabhachandani, P., Motwani, V., Cohen, N., Sarkar, S., Torchilin, V., & Konry, T. (2016) · Lab on a Chip · doi:10.1039/c5lc01139f · Cited by 193
Zhao, Q., Huang, L., Qin, G., Qiao, Y., Ren, F., Shen, C., Wang, S., Liu, S., Lian, J., Wang, D., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.009 · Cited by 191
Polak, R., de Rooij, B., Pieters, R., & den Boer, M. L. (2015) · Blood · doi:10.1182/blood-2015-03-634238 · Cited by 182
“Several studies report that the leukemic niche can induce drug resistance for both classical chemotherapeutic agents and newly developed targeted therapies.(9,44-46,50-52) The seminal papers by Straussman et al(44) andWilson et al(45) revealed the widespread potential for growth-factor–driven resistance tokinase inhib…”
BackgroundShen, S., Li, H.-J., Chen, K.-G., Wang, Y.-C., Yang, X.-Z., Lian, Z.-X., Du, J.-Z., & Wang, J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b01193 · Cited by 186
Mitochondria: gatekeepers of response to chemotherapy
Sarosiek, K. A., Ni Chonghaile, T., & Letai, A. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.08.003 · Cited by 171
In Vitro Human Cell Line Models to Predict Clinical Response to Anticancer Drugs
Niu, N., & Wang, L. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.170 · Cited by 162
The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance
Zhao, L., Liu, W., Xiao, J., & Cao, B. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.10.027 · Cited by 167
“There are multiple reasons for drug resistance, including the turning of tumor cells to a rescue pathway when the primary pathway is closed [45], the epigenetic inhibition of tumor suppressor proteins by miRNAs [46], the presence of a plastic subset of cancer stem-like cells with high drug-resistance, such as epitheli…”
BackgroundQiao, Y., Zhang, C., Li, A., Wang, D., Luo, Z., Ping, Y., Zhou, B., Liu, S., Li, H., Yue, D., et al. (2018) · Oncogene · doi:10.1038/onc.2017.387 · Cited by 166
Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype
Giuli, M. V., Giuliani, E., Screpanti, I., Bellavia, D., & Checquolo, S. (2019) · Journal of Oncology · doi:10.1155/2019/8707053 · Cited by 162
“For instance, stromal cells sustain cancer cell survival after genotoxic and targeted therapy through paracrine and juxtacrine signaling [109].”
BackgroundInnovative Human Three-Dimensional Tissue-Engineered Models as an Alternative to Animal Testing
Bédard, P., Gauvin, S., Ferland, K., Caneparo, C., Pellerin, È., Chabaud, S., & Bolduc, S. (2020) · Bioengineering · doi:10.3390/bioengineering7030115 · Cited by 158
Liang, C., Shi, S., Meng, Q., Liang, D., Ji, S., Zhang, B., Qin, Y., Xu, J., Ni, Q., & Yu, X. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.255 · Cited by 158
Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer
Plava, J., Cihova, M., Burikova, M., Matuskova, M., Kucerova, L., & Miklikova, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0960-z · Cited by 164
“tumor behavior in a complex manner [6].”
Unger, C., Kramer, N., Walzl, A., Scherzer, M., Hengstschläger, M., & Dolznig, H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.015 · Cited by 158
Enzyme-Instructed Self-Assembly: A Multistep Process for Potential Cancer Therapy
Zhou, J., & Xu, B. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00196 · Cited by 160
Heralding a new paradigm in 3D tumor modeling
Fong, E. L. S., Harrington, D. A., Farach‐Carson, M. C., & Yu, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.052 · Cited by 164
“Together, these culminate in the establishment of tumorstroma interactions that modulate tumor sensitivity - conferring resistance or synthetic lethality - depending on the class of therapeutics and the microenvironmental context [20].”
Decellularized Extracellular Matrix for Bioengineering Physiomimetic 3D in Vitro Tumor Models
Ferreira, L. P., Gaspar, V. M., & Mano, J. F. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.04.006 · Cited by 153
Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
Würth, R., Thellung, S., Bajetto, A., Mazzanti, M., Florio, T., & Barbieri, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.017 · Cited by 164
Li, W., Zhang, X., Wang, J., Li, M., Cao, C., Tan, J., Ma, D., & Gao, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.21635 · Cited by 159
“The initiation and progression of cancer metastasis is a complex course mediated by tumor cells together with their surrounding microenvironment [8].”
BackgroundAlexander, S., Weigelin, B., Winkler, F., & Friedl, P. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.07.001 · Cited by 168
BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance
Duarte, A. A., Gogola, E., Sachs, N., Barazas, M., Annunziato, S., de Ruiter, J. R., Velds, A., Blatter, S., Houthuijzen, J. M., van de Ven, M., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4535 · Cited by 152
Yi, Y., Zeng, S., Wang, Z., Wu, M., Ma, Y., Ye, X., Zhang, B., & Liu, H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.12.021 · Cited by 156
Tumor microenvironment-mediated chemoresistance in breast cancer
Velaei, K., Samadi, N., Brazvan, B., & Rad, J. S. (2016) · The Breast · doi:10.1016/j.breast.2016.09.002 · Cited by 149
Breast Cancer Cell Invasion into a Three Dimensional Tumor-Stroma Microenvironment
Truong, D., Puleo, J., Llave, A., Mouneimne, G., Kamm, R. D., & Nikkhah, M. (2016) · Scientific Reports · doi:10.1038/srep34094 · Cited by 135
Che, Y., Wang, J., Li, Y., Lu, Z., Huang, J., Sun, S., Mao, S., Lei, Y., Zang, R., Sun, N., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0808-2 · Cited by 151
Davies, E. J., Dong, M., Gutekunst, M., Närhi, K. M., Zoggel, H. J. A. A. V., Blom, S., Nagaraj, A. S., Metsalu, T., Oswald, E., Erkens‐Schulze, S., et al. (2015) · Scientific Reports · doi:10.1038/srep17187 · Cited by 146
New insights on sorafenib resistance in liver cancer with correlation of individualized therapy
Zhang, C., Wei-Qi, J., & Jin, D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188382 · Cited by 138
Karjalainen, R., Pemovska, T., Popa, M. L., Liu, M., Javarappa, K. K., Majumder, M. M., Yadav, B., Tamborero, D., Tang, J. P., Bychkov, D., et al. (2017) · Blood · doi:10.1182/blood-2016-02-699363 · Cited by 129
Impact of the spheroid model complexity on drug response
Hoffmann, O. I., Ilmberger, C., Magosch, S., Joka, M., Jauch, K.-W., & Mayer, B. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.02.029 · Cited by 125
Organoid systems to study the human female reproductive tract and pregnancy
Alzamil, L., Νικολακοπούλου, Κ., & Turco, M. Y. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0565-5 · Cited by 126
Aldinucci, D., Celegato, M., & Casagrande, N. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.007 · Cited by 118
Glucocorticoids in multiple myeloma: past, present, and future
Burwick, N. R., & Sharma, S. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3465-8 · Cited by 121
Anticancer drug discovery using multicellular tumor spheroid models
Zanoni, M., Pignatta, S., Arienti, C., Bonafè, M., & Tesei, A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1570129 · Cited by 117
Exosomes: Their Role in Pathogenesis, Diagnosis and Treatment of Diseases
Aheget, H., Mazini, L., Martín, F., Belqat, B., Marchal, J. A., & Benabdellah, K. (2020) · Cancers · doi:10.3390/cancers13010084 · Cited by 120
“One of these mechanisms is related to the decrease in drug penetrance in the tumor microenvironment due to a desmoplastic reaction [162].”
BackgroundFan, G., Yu, B., Tang, L., Zhu, R., Chen, J., Zhu, Y., Huang, H., Zhou, L., Liu, J., Wang, W., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj5705 · Cited by 128
“These findings provide previously unknown mechanistic insights into the plasticity of drug resistance and offer a rationale for the reversal strategy of therapeutic resistance ( 88 ).”
BackgroundŠevčíková, A., Izoldova, N., Števurková, V., Kasperova, B., Chovanec, M., Čierniková, S., & Mego, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010488 · Cited by 112
“Different mechanisms of drug chemoresistance have been described, related to genetic alterations, DNA damage repair, epigenetic modifications, deregulation of apoptosis, autophagy, and changes in the tumor microenvironment [1,2].”
BackgroundChen, W., Yang, C., Wang, S., Shi, D., Zhang, C., Lin, X., & Xiong, B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s198126 · Cited by 107
“Recently, accumulating evidence have suggested that the tumor microenvironment plays an important role in the development of tumor chemoresistance.(23,24) M2 macrophages are prominent component in the CRC microenvironment associated with tumor progression and poor prognosis.”
BackgroundGenini, D., Brambilla, L., Laurini, E., Merulla, J., Civenni, G., Pandit, S., D'Antuono, R., Perez, L., Levy, D. E., Pricl, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615730114 · Cited by 106
“Notably, limited nutrient and glucose availability are commonly faced by cancer cells in the tumor microenvironment in vivo (24, 45, 46).”
BackgroundThree dimensional in vitro models of cancer: Bioprinting multilineage glioblastoma models
Hermida, M. A., Kumar, J. D., Schwarz, D., Laverty, K. G., Bartolo, A. D., Ardron, M., Bogomolnijs, M., Clavreul, A., Brennan, P. M., Wiegand, U. K., et al. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.100658 · Cited by 111
The tumor microenvironment shapes hallmarks of mature B-cell malignancies
Shain, K. H., Dalton, W. S., & Tao, J. (2015) · Oncogene · doi:10.1038/onc.2014.403 · Cited by 114
In vitro 3d cultures to model the tumor microenvironment
Fontana, F., Marzagalli, M., Sommariva, M., Gagliano, N., & Limonta, P. (2021) · Cancers · doi:10.3390/cancers13122970 · Cited by 103
3D cancer models: One step closer to in vitro human studies
Manduca, N., Maccafeo, E., Maria, R. D., Sistigu, A., & Musella, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175503 · Cited by 108
Whitson, R. J., Lee, A. G., Urman, N. M., Mirza, A., Yao, C., Brown, A. S., Li, J., Shankar, G., Fry, M. A., Atwood, S. X., et al. (2018) · Nature Medicine · doi:10.1038/nm.4476 · Cited by 107
“Defining the role of growth cues within the tumor microenvironment remains a growing area of investigation 6-8 .”
PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer
Shi, Y., Niu, Y., Yuan, Y., Li, K., Zhong, C., Qiu, Z., Li, K., Zhu, L., Yang, Z., Zuo, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37542-5 · Cited by 102
Peela, N., Truong, D. D., Saini, H., Chu, H., Mashaghi, S., Ham, S. L., Singh, S. K., Tavana, H., Mosadegh, B., & Nikkhah, M. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.04.017 · Cited by 102
Cancer stem cells as a therapeutic target in bladder cancer
Aghaalikhani, N., Rashtchizadeh, N., Shadpour, P., Allameh, A., & Mahmoodi, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26916 · Cited by 104
de la Torre, P., Pérez-Lorenzo, M. J., Alcazar-Garrido, A., & Flores, A. I. (2020) · Molecules · doi:10.3390/molecules25030715 · Cited by 109
“Likewise, the tumor microenvironment has been implicated in tumor response to therapy and contributes to both intrinsic and acquired drug resistance [14].”
BackgroundLessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R. A., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 104
Choi, Y.-M., Lee, H., Ann, M., Song, M., Rheey, J., & Jang, J. (2023) · Biofabrication · doi:10.1088/1758-5090/acd95f · Cited by 94
Ramamonjisoa, N., & Ackerstaff, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00003 · Cited by 93
“Tumor–Stroma interactions Studying tumor–stroma interactions in vivo enables the comprehensive characterization of the TME and its impact on treatment efficacy, potentially leading to improved diagnosis, to the identification of new treatment targets, and closing further the gap between preclinical and clinical studie…”
BackgroundCostea, T., Vlad, O., Miclea, L. C., Ganea, C., Szöllõsi, J., & Mocanu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020401 · Cited by 101
Construction of tumor organoids and their application to cancer research and therapy
Lv, J., Du, X., Wang, M., Su, J., Wei, Y., & Xu, C. (2024) · Theranostics · doi:10.7150/thno.91362 · Cited by 95
“However, PDC models are oversimplified and fail to recapitulate the original tumors’ structural, physiological, and transcriptional characteristics [4].”
BackgroundOrganoid Models for Precision Cancer Immunotherapy
Sun, C., Lan, H., Fang, X., Yang, X., & Jin, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.770465 · Cited by 106
Giacomini, A., Chiodelli, P., Matarazzo, S., Rusnati, M., Presta, M., & Ronca, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.024 · Cited by 94
“Also, emerging evidences emphasize the ability of stromal cells to modulate tumor cell resistance or sensitization to different classes of therapeutics, depending on the specific microenvironmental context [85].”
3D In Vitro Model for Breast Cancer Research Using Magnetic Levitation and Bioprinting Method
Leonard, F., & Godin, B. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3444-7_21 · Cited by 94
Sarcoma Spheroids and Organoids—Promising Tools in the Era of Personalized Medicine
Colella, G., Fazioli, F., Gallo, M., Chiara, A. D., Apice, G., Ruosi, C., Cimmino, A., & de Nigris, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020615 · Cited by 96
“Spheroids developed much earlier resistance to doxorubicin than two-dimensional cell cultures, due to a limited penetration of the drug into the deeper layers of spheroids as a result of cell adhesion between tumor and stroma cells in the 3D systems [82,83].”
BackgroundLeto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
“, HGF, sustain the potential but understudied contribution of tumor-stromal interactions in influencing drug response in mCRCs [104, 120, 121].”
Roadblocks to translational advances on metastasis research
Brabletz, T., Lyden, D. C., Steeg, P. S., & Werb, Z. (2013) · Nature Medicine · doi:10.1038/nm.3327 · Cited by 93
Metadata
- Authors
- McMillin, D. W., Negri, J. M., & Mitsiades, C. S.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Corresponding author
- Mitsiades, Constantine S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-03
- Volume
- 12
- Issue
- 3
- Pages
- 217-228
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1980669422
- Cited by
- 474
- References
- 150
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 27 · 2023: 34 · 2022: 29 · 2021: 43 · 2020: 41 · 2019: 33 · 2018: 49 · 2017: 56 · 2016: 41 · 2015: 40 · 2014: 27 · 2013: 16
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (R0-1 50947)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Keywords
- tumor microenvironment, stromal cells, drug resistance, drug sensitivity, anticancer drug discovery, preclinical models, orthotopic xenograft, metastasis
- MeSH terms
- Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Drug Screening Assays, Antitumor, Humans, Neoplasms, Stromal Cells, Drug Resistance, Neoplasm, Drug Discovery, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.